Fidia Farmaceutici, inaugurated the new department for the production of biological drugs

Fidia Farmaceutici, a world leader in the research, development, production and marketing of innovative products, especially those based on hyaluronic acid and its derivatives, has inaugurated a new department dedicated to the production of biological drugs and a training center at its headquarters in Abano Terme, which will be dedicated to the specialized training of doctors and surgeons.

The production department, part of a broader industrial development plan, represents a strategic asset for the Group, destined to expand its production capacity and strengthen its positioning in the global pharmaceutical sector. With a total surface area of ​​3,500 square meters distributed over several floors, the new department was created with a total investment of approximately 50 million euros, further confirming Fidia Farmaceutici's commitment to innovation in production processes and industrial efficiency. The new site will be dedicated to the production of biological drugs, such as enzymes, hormones, blood products, monoclonal antibodies, serums, vaccines and immunoglobulins, which are increasingly crucial in responding to advanced therapeutic needs. The new production hub represents the state of the art of technological innovation applied to pharmaceutical production. It is equipped with the most modern automation technologies and has been designed according to the highest technological and quality standards, in line with the most recent international regulatory requirements for the production of biological drugs.

Thanks to the adoption of green solutions including the use of liquid nitrogen instead of traditional refrigeration units and the rationalization of the volumes of sterile areas, a reduction in energy consumption of 30% is also expected compared to current standards. The project, designed to be scalable and highly innovative, has already started the inclusion of new qualified professional figures, with highly specialized roles that are integrated into the team, strengthening the technical-scientific heritage of the company.

Together with the new production department, Fidia is also opening the doors to its new Training Center, a modern and highly technological space designed to offer excellent training to doctors and surgeons. The center was created to enhance learning through direct observation of clinical procedures, thanks to the possibility of following live surgery sessions transmitted in real time from one or more operating rooms, equipped with an advanced system of high-definition cameras integrated into the instruments and the surgical table. The Training Center will be inaugurated by ophthalmology specialists, who will be able to watch the operations inside a cutting-edge multimedia room, designed to offer an immersive and highly educational experience. In addition, for this first specialist area, an ophthalmic dry lab will also be available, equipped with latest-generation simulators to practice cataract and retinal operations: a practical, safe and ethical method that integrates theoretical and observational training with direct experience, in a high-tech context.

The Training Center represents the first step of a broader project, which includes progressive development in additional therapeutic areas, with the aim of creating an interdisciplinary environment that is in step with the evolution of medical practice, creating a cutting-edge training center in the area that welcomes professionals from all over the world. This initiative is part of the long-term path with which Fidia confirms its concrete commitment alongside doctors, and which also includes the organization of a growing number of important training events (such as the Fidia Academy) in-house, offering innovative tools and opportunities for professional growth in line with the challenges of modern medicine and at the same time enhancing the territory and its resources.

The inauguration was attended by numerous authorities, including the President of the Veneto Region, Luca Zaia, the Mayor of Abano Terme, Federico Barbierato and the President of Confindustria Veneto Est Paola Carron, whose contribution was essential to allow the project to be completed on schedule. Carlo Pizzocaro, President and CEO of Fidia Farmaceutici, stated: "With these investments we are strengthening an industrial hub of excellence that combines efficiency, sustainability and innovation, in line with the highest international standards. It is an important step in our growth path, which confirms our desire to consolidate our authority and competitiveness. We wanted to combine production innovation with a significant investment in training, because we believe that the development of skills is an essential strategic element to face future challenges and contribute to the growth of scientific and clinical culture worldwide". Rossella Pellizzari, head of the Abano Terme plant at Fidia Farmaceutici, adds: «This project is the result of a journey lasting about six years, involving hundreds of highly specialized professionals and a total investment of over 50 million euros. A concrete commitment to innovation, with the aim of building tomorrow's production excellence today».